Patents Examined by Brian Gangle
-
Patent number: 11965017Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: October 8, 2020Date of Patent: April 23, 2024Assignee: InhibRx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Patent number: 11965029Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 4, 2021Date of Patent: April 23, 2024Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 11957751Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: February 12, 2021Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 11959066Abstract: A Pseudomonas monteilii strain with salinity-alkalinity tolerance is provided. The strain is Pseudomonas monteilii 9-2, which has been deposited in China General Microbiological Culture Collection Center (CGMCC) on Oct. 25, 2021, with an accession number of CGMCC No. 23666; and an internal transcribed spacer (ITS) sequence is shown in SEQ ID NO: 1. This application further provides an application of the Pseudomonas monteilii strain in the degradation of petroleum hydrocarbons in a saline-alkali environment.Type: GrantFiled: January 4, 2023Date of Patent: April 16, 2024Assignee: Northwest Institute of Eco-Environment and Resources, CASInventors: Yingqin Wu, Zhiyu Wang, Tong Wang, Longmiao Yuan, Yanhong Liu, Rong Ma
-
Patent number: 11957740Abstract: Compositions comprising the L complex or the M complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), methods of making, and methods of use to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.Type: GrantFiled: March 13, 2021Date of Patent: April 16, 2024Assignee: Prime Bio, Inc.Inventors: Bal Ram Singh, Raj Kumar
-
Patent number: 11951140Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.Type: GrantFiled: May 4, 2023Date of Patent: April 9, 2024Assignee: Seed Health, Inc.Inventors: Tye Jensen, Joseph E. Kovarik
-
Patent number: 11951207Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.Type: GrantFiled: June 28, 2017Date of Patent: April 9, 2024Assignee: Celltrion Inc.Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Su Hyeon Hong, Yeon Kyeong Shin
-
Patent number: 11951139Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.Type: GrantFiled: August 23, 2022Date of Patent: April 9, 2024Assignee: Seed Health, Inc.Inventor: Joseph E. Kovarik
-
Patent number: 11953503Abstract: Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.Type: GrantFiled: January 14, 2019Date of Patent: April 9, 2024Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Harald Althaus, Thorsten Keller
-
Patent number: 11952576Abstract: A novel method of diluting the structures in the cell population, such that individual cells, dependent on the activity of the structures, become single measurement devices. This can be applied to all Bacterial Microcomparments (“BMCs”), organelles, and macromolecules, and could provide a universal method for the design of novel ones and understanding of the diverse structures. In one aspect the present invention provides A method of creating a bacterial strain with inducible and detectable carboxysomes. The method includes the steps of incorporating a labeled carbon-fixation enzyme into the genome of a bacterium; deleting all or a portion of the ccm operon from the bacterium; and reintroducing a ccm operon comprising an inducible promoter to create a ?ccm+ strain.Type: GrantFiled: November 16, 2020Date of Patent: April 9, 2024Assignee: The Regents of the University of Colorado, a body corporateInventors: Jeffrey Carlyle Cameron, Nicholas C. Hill, Jian Wei Tay, Sabina Altus, David Matthew Bortz, Kristin Ann Moore
-
Patent number: 11952597Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: July 7, 2020Date of Patent: April 9, 2024Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Patent number: 11946927Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.Type: GrantFiled: August 20, 2019Date of Patent: April 2, 2024Inventors: Bruce R. Yacyshyn, Mary E. Yacyshyn
-
Patent number: 11944675Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: October 2, 2020Date of Patent: April 2, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Fabiana Fernandez, Michael Kowarik, Michael Wacker, Michael Wetter
-
Patent number: 11938179Abstract: Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.Type: GrantFiled: August 10, 2021Date of Patent: March 26, 2024Assignee: Novavax, Inc.Inventors: Jing-Hui Tian, Ye Liu, Gale Smith, Gregory Glenn, David Flyer
-
Patent number: 11939592Abstract: An object of the present invention is to provide a recombinant phage having high safety and excellent practicality and usefulness. Provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a bacteriophage genome in which a part of a virion constituent gene is deleted is stored in a head, and a method for preparing the same. In addition, provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a plasmid having a packaging site and encoding a target gene is stored in a head, and a method for preparing the same.Type: GrantFiled: December 5, 2019Date of Patent: March 26, 2024Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEMInventors: Shoichi Mitsunaka, Hiroki Ando
-
Patent number: 11939396Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.Type: GrantFiled: June 30, 2020Date of Patent: March 26, 2024Assignee: Genentech, Inc.Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
-
Patent number: 11932670Abstract: Provided herein are glycosylated ComP proteins, fragments and fusion proteins thereof, and methods of making, for example, for use in the production of conjugate vaccines. Also provided herein are conjugate vaccines against diseases including bacterial diseases.Type: GrantFiled: June 14, 2019Date of Patent: March 19, 2024Assignee: VaxNewMo LLCInventors: Christian Harding, Mario Feldman
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11925677Abstract: A method for treating chronic pancreatitis and diabetes type II in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof.Type: GrantFiled: July 11, 2022Date of Patent: March 12, 2024Assignee: Penland FoundationInventor: Roland M. Williams
-
Patent number: 11918636Abstract: An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.Type: GrantFiled: July 1, 2021Date of Patent: March 5, 2024Assignee: SCANDINAVIAN BIOPHARMA HOLDING AB, C/O ETVAX ABInventors: Ann-Mari Svennerholm, Joshua Tobias, Nils Carlin, Jan Holmgren